Literature DB >> 26309524

Efficacy study of edaravone and acetylcysteine towards bleomycin-induced rat pulmonary fibrosis.

Wen-Cheng Yu1, Li-Ying Tian1, Wei Cheng1.   

Abstract

The aim of this study was to investigate the interventional effects of Edaravone (EDA) and Acetylcysteine (NAC) towards the Bleomycin (BLM)-induced pulmonary fibrosis. 48 Wistar rats were divided into the control group, the BLM group, the hormone group, the EDA group, the NAC group and the combination group. After performing the BLM intratracheal injection to prepare the pulmonary fibrosis model, the rats were administrated EDA, dexamethasone (DEX), NAC and EDA+NAC combined intervention, the lung HRCT examination was performed on the 7(th), 21(st) and 31(st) day. On the 31(st) day, the rats were killed for the detection of serum malondialdehyde (MDA) and superoxide dismutase (SOD) contents; the lung tissues were performed the HE and Masson staining and determined the hydroxyproline content. The rats of the intervention group exhibited mild hypoxic phenomenon, with less ground-glass shadow and consolidated shadow than the BLM group, the MDA content decreased while the SOD content increased, and the degrees of alveolar inflammatory cell infiltration and fibrosis were low. The results of the EDA group and the NAC group were similar, and those of the combination group were better. EDA could inhibit the BLM-induced pulmonary fibrosis through adjusting the oxidant/antioxidant imbalance, with the effect similar to NAC, and the combined application of these 2 drugs were much more effective.

Entities:  

Keywords:  Pulmonary fibrosis; acetylcysteine; bleomycin; edaravone

Year:  2015        PMID: 26309524      PMCID: PMC4538007     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  20 in total

Review 1.  Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis.

Authors:  Corrine R Kliment; Tim D Oury
Journal:  Free Radic Biol Med       Date:  2010-05-07       Impact factor: 7.376

Review 2.  Oxidant-antioxidant imbalance as a potential contributor to the progression of human pulmonary fibrosis.

Authors:  Vuokko L Kinnula; Marjukka Myllärniemi
Journal:  Antioxid Redox Signal       Date:  2008-04       Impact factor: 8.401

3.  Pretreatment with edaravone reduces lung mitochondrial damage in an infant rabbit ischemia-reperfusion model.

Authors:  Wanshan Qiu; Haiyong Gu; Liang Zheng; Jianwei Zhou; Duan Chen; Yijiang Chen
Journal:  J Pediatr Surg       Date:  2008-11       Impact factor: 2.545

4.  Attenuation of bleomycin-induced lung injury and oxidative stress by N-acetylcysteine plus deferoxamine.

Authors:  Kelly C Teixeira; Fernanda S Soares; Luís G C Rocha; Paulo C L Silveira; Luciano A Silva; Samuel S Valença; Felipe Dal Pizzol; Emilio L Streck; Ricardo A Pinho
Journal:  Pulm Pharmacol Ther       Date:  2007-08-29       Impact factor: 3.410

5.  A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Williamson Z Bradford; Socorro Castro-Bernardini; Elizabeth A Fagan; Ian Glaspole; Marilyn K Glassberg; Eduard Gorina; Peter M Hopkins; David Kardatzke; Lisa Lancaster; David J Lederer; Steven D Nathan; Carlos A Pereira; Steven A Sahn; Robert Sussman; Jeffrey J Swigris; Paul W Noble
Journal:  N Engl J Med       Date:  2014-05-18       Impact factor: 91.245

Review 6.  The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?

Authors:  Antje Moeller; Kjetil Ask; David Warburton; Jack Gauldie; Martin Kolb
Journal:  Int J Biochem Cell Biol       Date:  2007-08-30       Impact factor: 5.085

7.  Inhibition of fibrosis and inflammation by triple therapy with pirfenidone, edaravone and erythropoietin in rabbits with drug-induced lung injury: comparison of CT imaging and pathological findings.

Authors:  Shobu Watanabe; Norihisa Nitta; Akinaga Sonoda; Ayumi Nitta-Seko; Shinichi Ohta; Keiko Tsuchiya; Hideji Otani; Yuki Tomozawa; Yukihiro Nagatani; Kenichi Mukaisho; Masashi Takahashi; Kiyoshi Murata
Journal:  Exp Ther Med       Date:  2013-09-18       Impact factor: 2.447

8.  A mouse model of chronic idiopathic pulmonary fibrosis.

Authors:  Nathachit Limjunyawong; Wayne Mitzner; Maureen R Horton
Journal:  Physiol Rep       Date:  2014-02-25

9.  Spironolactone attenuates bleomycin-induced pulmonary injury partially via modulating mononuclear phagocyte phenotype switching in circulating and alveolar compartments.

Authors:  Wen-Jie Ji; Yong-Qiang Ma; Xin Zhou; Yi-Dan Zhang; Rui-Yi Lu; Zhao-Zeng Guo; Hai-Ying Sun; Dao-Chuan Hu; Guo-Hong Yang; Yu-Ming Li; Lu-Qing Wei
Journal:  PLoS One       Date:  2013-11-19       Impact factor: 3.240

10.  Double-blind controlled trial of lecithinized superoxide dismutase in patients with idiopathic interstitial pneumonia - short term evaluation of safety and tolerability.

Authors:  Koichiro Kamio; Arata Azuma; Ken Ohta; Yukihiko Sugiyama; Toshihiro Nukiwa; Shoji Kudoh; Tohru Mizushima
Journal:  BMC Pulm Med       Date:  2014-05-17       Impact factor: 3.317

View more
  3 in total

1.  Beneficial effects of N-acetylcysteine on protease-antiprotease balance in attenuating bleomycin-induced pulmonary fibrosis in rats.

Authors:  Ritu Kulshrestha; Apoorva Pandey; Amteshwar Jaggi; Surendra Bansal
Journal:  Iran J Basic Med Sci       Date:  2020-03       Impact factor: 2.699

2.  Therapy with high-dose long-term antioxidant free radicals for severe paraquat poisoning: A pilot study.

Authors:  Shunlin Hu; Chuanhu Qiao; Zhengli Yuan; Min Li; Jiangfeng Ye; Huimin Ma; Jinghui Wang; Siyi Xin; Jing Zhang
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

3.  Retrospective study of clinical features and prognosis of edaravone in the treatment of paraquat poisoning.

Authors:  Ren Yi; Yang Zhizhou; Sun Zhaorui; Zhang Wei; Chen Xin; Nie Shinan
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.